论文部分内容阅读
采用免疫组化法对69例膀胱移行细胞癌中P_(53)蛋白及增殖细胞核抗原(PCNA)进行检测。发现膀胱癌中P_(53)蛋白的过度表达与病理分级无关,而与临床分期及预后有关。PCNA-LI与病理分极、临床分期及预后均相关,随着肿瘤分级、分期的增高,PCNA-LI呈明显上升趋势;P_(53)蛋白过度表达或PCNA高表达组术后5年生存率明显低于P_(53)蛋白非过度表达或PCNA低表达组。结果表明:P_(53)蛋白的过度表达在膀胱癌发生、发展中起着一定作用,PCNA是判定膀胱癌恶性程度及预后的重要指标,同时发现膀胱癌中P_(53)蛋白的过度表达与PCNA-LI相关。
Immunohistochemistry was used to detect the expression of P 53 protein and proliferating cell nuclear antigen (PCNA) in 69 cases of bladder transitional cell carcinoma. It was found that overexpression of P53 protein in bladder cancer has nothing to do with the pathological grade, but related to the clinical stage and prognosis. PCNA-LI was correlated with the pathology, the clinical stage and the prognosis. The PCNA-LI showed an obvious upward trend with the increase of tumor grade and stage. The 5-year survival rate of PCNA-LI overexpression or PCNA overexpression group Which was significantly lower than that of P53 protein non-overexpression or PCNA low expression group. The results showed that overexpression of P53 protein plays an important role in the occurrence and development of bladder cancer. PCNA is an important index to determine the malignant degree and prognosis of bladder cancer. The overexpression of P53 protein in bladder cancer is associated with PCNA-LI related.